A-769662 inhibits adipocyte glucose uptake in an AMPK-independent manner.

Franziska Kopietz,Olga Göransson,Fatmah Alghamdi,Eva Degerman,Silvia Bijland,Ian P Salt,Kei Sakamoto,Yazeed Alshuweishi

doi:10.1042/bcj20200659

Abstract

Activation of AMP-activated protein kinase (AMPK) is considered a valid strategy for the treatment of type 2 diabetes. However, despite the importance of adipose tissue for whole-body energy homeostasis, the effect of AMPK activation in adipocytes has only been studied to a limited extent and mainly with the AMP-mimetic 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR), which has limited specificity. The aim of this study was to evaluate the effect of the allosteric AMPK activators A-769662 and 991 on glucose uptake in adipocytes. For this purpose, primary rat or human adipocytes, and cultured 3T3-L1 adipocytes, were treated with either of the allosteric activators, or AICAR, and basal and insulin-stimulated glucose uptake was assessed. Additionally, the effect of AMPK activators on insulin-stimulated phosphorylation of Akt and Akt substrate of 160 kDa was assessed. Furthermore, primary adipocytes from ADaM site binding drug-resistant AMPKβ1 S108A knock-in mice were employed to investigate the specificity of the drugs for the observed effects. Our results show that insulin-stimulated adipocyte glucose uptake was significantly reduced by A-769662 but not 991, yet neither activator had any clear effects on basal or insulin-stimulated Akt/AS160 signaling. The use of AMPKβ1 S108A mutant-expressing adipocytes revealed that the observed inhibition of glucose uptake by A-769662 is most likely AMPK-independent, a finding which is supported by the rapid inhibitory effect A-769662 exerts on glucose uptake in 3T3-L1 adipocytes. These data suggest that AMPK activation per se does not inhibit glucose uptake in adipocytes and that the effects of AICAR and A-769662 are AMPK-independent.

Highlights

AMP-activated protein kinase (AMPK) is a highly conserved heterotrimeric protein composed of a catalytic -subunit and two regulatory subunits, and
While we recently described the effect of aminoimidazole-4-carboxamide-1- -d-ribofuranoside (AICAR) and the allosteric drug and metabolite (ADaM) site AMPK activators on lipolysis, adipocyte glucose uptake has only been studied using AICAR [18,19,20]
In order to investigate the effect of AMPK activation on glucose uptake in different adipocyte models, primary rat or human adipocytes or cultured 3T3-L1 cells were preincubated with either of the three AMPK activators AICAR, A-769662 or 991, prior to incubation without or with insulin

Summary

Introduction

AMP-activated protein kinase (AMPK) is a highly conserved heterotrimeric protein composed of a catalytic -subunit and two regulatory subunits, and. In the event of decreasing cellular energy levels, i.e. an increase in AMP and ADP, AMPK becomes activated. This activation involves the binding of AMP and/or ADP to the regulatory -. AMPK constitutes a key player in the regulation of cellular and whole-body energy homeostasis. Activation of AMPK is considered a useful strategy for the treatment of type 2 diabetes (T2D), mainly due to beneficial effects observed in liver and muscle tissue, including decreased lipid accumulation and increased glucose uptake, respectively [2, 3].

Objectives

Results

Conclusion